ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019

SAN DIEGO—(BUSINESS WIRE)—Apr. 2, 2019—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will present at the 18^th AnnualNeedham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m.Eastern Time in New York City.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through May 9, 2019.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has developed and iscommercializing the first and only medicine approved for the treatmentof hallucinations and delusions associated with Parkinson’s diseasepsychosis. In addition, ACADIA has ongoing clinical development effortsin additional areas with significant unmet need, includingdementia-related psychosis, schizophrenia inadequate response,schizophrenia-negative symptoms, major depressive disorder and Rettsyndrome. This press release and further information about ACADIA can befound at: www.acadia-pharm.com.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:

ACADIA Pharmaceuticals Inc.
MarkJohnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Media Contact:

ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com